Lyn Jones completed his PhD studies in synthetic organic chemistry at the University of Nottingham, and his postdoctoral research at The Scripps Research Institute, California, in chemical biology. He joined Pfizer Sandwich (UK) as a medicinal chemistry team leader, eventually becoming Head of Chemical Biology and Lead Discovery Technologies. He transferred to Pfizer Cambridge (USA) to become Head of Chemistry for Rare Disease Research and Head of Chemical Biology. He then helped establish Jnana Therapeutics as Head of Chemistry and Chemical Biology, before moving to Dana-Farber Cancer Institute in Boston as Chief Scientist of the Center for Protein Degradation. He is currently Principal Investigator and Faculty Member of the Department of Pediatric Oncology and Chemical Biology Program at DFCI, and his lab focuses on the development of next-generation covalent chemical biology with the objective of expanding the druggable proteome.